Inspire Medical Stock Soars 40% on CMS Code Update

CMS Announces New Reimbursement Codes, Boosting INSP Shares

Inspire Medical Systems (NYSE:INSP) shares surged by 40% following an announcement from the Centers for Medicare & Medicaid Services (CMS) about new product-specific reimbursement codes. This development signals a clearer and potentially more stable payment pathway for the company's hypoglossal nerve stimulation devices used to treat sleep apnea.

Situational Overview

In its MLN Connects Newsletter, CMS acknowledged recent confusion surrounding reimbursement for hypoglossal nerve stimulation procedures. To address this, the agency will add six new Healthcare Common Procedure Coding System (HCPCS) codes. Three codes (C8007-C8009) are specific to Inspire V procedures, while three others (C8011-C8013) are for competitor Nyxoah's devices. These new codes are scheduled to become effective on January 1, 2026, for the April 2026 Integrated Outpatient Code Editor update.

Market and Economic Impact

The market reacted positively as the new codes are expected to expedite clarity on permanent, product-specific payment methods. According to a Keybanc analyst, this move will help transition away from the current, less specific coding practice involving code 64582 with a -52 modifier. This timeline is significantly faster than the 2028 target Inspire's management had previously estimated for securing a new Category 1 code, representing a major regulatory win for the company.

Summary

The introduction of dedicated HCPCS codes by CMS is a pivotal development for Inspire Medical and the broader neurostimulation device market. It reduces uncertainty and provides a more direct route to standardized reimbursement. Investors will closely watch the implementation process and the final payment rates assigned to these codes as the 2026 effective date approaches.

FAQ

Q: Why did Inspire Medical's stock price increase so sharply?
A: The stock surged 40% after the Centers for Medicare & Medicaid Services (CMS) announced it would create new, specific reimbursement codes for the company's medical devices, which is expected to secure and clarify future revenue streams.

Q: What are the new codes for?
A: The new HCPCS codes are for hypoglossal nerve stimulation procedures, with specific codes assigned to devices from Inspire Medical and its competitor, Nyxoah, to treat obstructive sleep apnea.

Q: When will these changes take effect?
A: The new codes will be effective on January 1, 2026, and will be included in the Integrated Outpatient Code Editor update scheduled for April 2026.

Source: Investing.com